Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

Inclusion Criteria: Here's a concise English translation: * Voluntarily signed informed consent to participate in a non-interventional study. * Hospitalized patients with moderate COVID-19 requiring anticoagulant therapy for prevention of thrombotic complications. * Men and women aged ≥18 years. * Patients prescribed Dimolegin® 10 mg enteric-coated film tablets for thromboprophylaxis as part of routine care for moderate COVID-19. * Ability to understand study requirements, provide written consent and comply with protocol procedures. Exclusion Criteria: * Hypersensitivity to Dimolegin®. * Clinically significant active bleeding at screening. * Concomitant therapy with fibrinolytics or other anticoagulants. * Anemia or thrombocytopenia. * Thrombophilia. * Other coagulopathies or contraindications to anticoagulants. * Liver disease with impaired function or biliary tract disease. * Creatinine clearance \<30 mL/min. * Gastrointestinal disorders affecting absorption. * Pregnancy, breastfeeding, suspected pregnancy, or planned pregnancy within 3 months (including male patients whose partners plan pregnancy). * Use of investigational or unapproved drugs, or participation in another clinical study within 90 days before therapy start. * History or suspicion of alcohol or drug abuse, dependence, or addiction. * Any other condition that, in the investigator's opinion, could interfere with study participation or pose undue risk.